OL-041 Current distribution of HBV serological markers in chronic HBV patients and its significance in Mongolia

Abstract

Objectives: At present, there is no consensus of telbivudine (LdT) treatment for chronic hepatitis B (CHB) patients who have poor response to adevofir dipivoxil (ADV) monotherapy. The aim of this study was to assess the therapeutic effectiveness of LdT, administered in combination with ADV in CHB patients with poor response to ADV monotherapy. Methods: Twenty-four adult outpatients aged >18 years with HBVDNA 103 copies/mL and normal alanine aminotransferase (ALT) after at least 48 weeks of ADV initial monotherapy were included and immediately received ADV plus LdT combination treatment in this prospective study. HBVDNA and ALT levels were checked every 3 month. The proportions of patients who achieved virologic response (VR, undetectable HBV-DNA [<103 copies/mL]) were analyzed, and serum creatine kinase (CK) and creatinine (Cr) after combination therapy were observed. Results: At baseline of combination treatment, the mean level of HBVDNA was 4.05 log (10) copies/mL. Compared with baseline, the mean decrease in HBVDNA level at week 12 and 24 were 0.89 log10 and 1.31 log10 copies/mL, respectively, and the decreasing was significant (p < 0.001for week 12, and p < 0.001 for week 24). The VR rate was 41.7% and 66.7% at weeks 12 and 24, respectively, and the difference in VR between week 12 and 24 was significant (p = 0.003). During the initial 24 weeks combination therapy, no elevated ALT, CK, and Cr were detected. Conclusions: Adding LdT may be a good choice for CHB patients with poor response to ADV monotherapy. And further long-term study was necessary to confirm the results.